Overview
At PrecisionGenetics, we have developed a groundbreaking platform that leverages CRISPR technology for the treatment of rare genetic disorders. Our team consists of experienced professionals in genetics, biochemistry, and clinical research. After successfully completing our initial laboratory tests, we are ready to move into the clinical trial phase. Currently, we have promising results indicating that our gene-editing therapies can significantly improve patient outcomes, reducing the symptoms of previously untreatable conditions. We are seeking $2.5 million in funding to expand our clinical trials and optimize our production process. This investment will enable us to transition from a research-focused entity to a clinical-stage biotech company. We believe that with sufficient funding, we can expedite the timeline for our therapies' availability, attract strategic partnerships, and ultimately save lives while generating significant returns for our investors. Our commitment to transparency and ethical standards drives our innovation, and we have already acquired a patent for our underlying technology. As we build our clinical database, we have established collaborations with leading…
Use of funds
The $2.5 million investment will be allocated as follows:
- Clinical Trials: $1.5 million for Phase I and Phase II trials to test the efficacy and safety of our therapies.
- Operational Costs: $700,000 for scaling our laboratory production capabilities and acquiring necessary equipment.
- Marketing and Partnerships: $300,000 to establish strategic partnerships and marketing efforts to raise awareness of our therapies in the healthcare community.
Open case
Open this case to get the detailed business plan and direct contact with the founder or seeker.